Mar 7, 2016 • 7:35 am EST Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Feb 1, 2016 • 7:05 am EST Corbus Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016
Jan 5, 2016 • 7:05 am EST Corbus Pharmaceuticals to Present at Biotech Showcase(TM) on January 12, 2016
Nov 23, 2015 • 7:05 am EST Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015
Oct 20, 2015 • 8:05 am EDT Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Oct 15, 2015 • 7:30 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
Oct 7, 2015 • 7:05 am EDT Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
Sep 22, 2015 • 7:00 am EDT Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis